CAS NO: | 17817-31-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced fromGlycine maxwith antioxidant, and anti-cancer activities. Desmethylglycitein binds directly toCDK1andCDK2in vivo, resulting in the suppressesCDK1andCDK2activity[1]. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1)[2]. Desmethylglycitein binds toPI3Kin an ATP competitive manner in the cytosol, where it inhibits the activity ofPI3Kand downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes[3]. | ||||||||||||||||||||||||
IC50& Target[1][2][3] |
| ||||||||||||||||||||||||
体外研究 (In Vitro) | Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity[1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells[1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% )[1]. Cell Viability Assay[1]
Western Blot Analysis[1]
Cell Cycle Analysis[1]
| ||||||||||||||||||||||||
体内研究 (In Vivo) | Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system[1].
| ||||||||||||||||||||||||
分子量 | 270.24 | ||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||
Formula | C15H10O5 | ||||||||||||||||||||||||
CAS 号 | 17817-31-1 | ||||||||||||||||||||||||
中文名称 | 4',6,7-三羟基异黄酮 | ||||||||||||||||||||||||
结构分类 |
| ||||||||||||||||||||||||
来源 |
| ||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 125 mg/mL(462.55 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|